Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes.

The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.

Inclusion Criteria:

• Patients must have ADHD, be outpatients, who are at least 6 years of age and not more than 11 years 8 months of age at Visit 1 so that all testing will be completed before the child reaches age 12.
• Patients must have moderately severe symptoms of ADHD.
• Patients must be able to swallow study drug capsules.

Exclusion Criteria:

• Patients must not have Bipolar disorder, psychosis, autism, Asperger's syndrome, pervasive developmental disorder, or seizure disorder.
• Patients must not have taken atomoxetine prior to starting the study.